Search clinical trials for: GP Peramprizumab Anlotinib

Total 1570 results

Hospital Avicenne

Terminated

Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation (SISCA)

CORONARY DISEASE

France
Novartis Pharmaceuticals

Active, not recruiting

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)

Chronic Myelogenous Leukemia

Belgium, Spain, Austria, Germany, Italy, France, Netherlands, Sweden, Japan, United States, Greece, United Kingdom, Bulgaria, Hungary, Argentina, Poland, Colombia, Ireland, Denmark
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Bladder Cancer

United States
Pamela L. Kunz
Genentech, Inc.

Terminated

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroblastoma | Multiple Endocrine Neoplasia | Pancreatic Neuroendocrine Tumors | Carcinoid Tumors | Adrenal Gland Tumors

United States
George Albert Fisher
Genentech, Inc.

Terminated

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
Hellenic Cooperative Oncology Group

Terminated

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

Advanced Non-Small Cell Lung Cancer

Greece
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular... and other conditions

United States
Chinese PLA General Hospital

Not yet recruiting

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Hepatocellular Carcinoma | Anlotinib | Thermal Ablation | PDL-1

China
Shi Yuankai

Recruiting

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head and Neck Squamous Cell Carcinoma

China
David Piccioni, M.D., Ph.D
Novartis

Completed

Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

Glioma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; OSI Pharmaceuticals

Completed

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer

United States
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Samsung Medical Center

Completed

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Lung Neoplasms | Neoadjuvant Therapy | Erlotinib

Korea, Republic of
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Air Force Military Medical University, China

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma

China
National Cancer Institute (NCI)

Completed

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Novartis Pharmaceuticals

No longer available

Nilotinib, for Patients With CML-CP or CML-AP

Chronic Myelogenous Leukemia (CML)
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib in PH+, BCR-, ABL+ CML Patients (CML0811)

Chronic Myeloid Leukemia

Italy
Novartis Pharmaceuticals

Completed

Tasigna in Glivec-resistant or Intolerant Patients in CML

CML | Nilotinib | Imatinib Resistant | Imatinib Intolerant

Korea, Republic of
Novartis Pharmaceuticals

Approved for marketing

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Mexico
Geisinger Clinic
Genentech, Inc.

Terminated

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
University of Alabama at Birmingham
Genentech, Inc.; OSI Pharmaceuticals

Completed

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma (RAD0503)

Cancer

United States
Hoffmann-La Roche

Completed

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (BIOTEC)

Carcinoma，Non-Small-Cell Lung

Romania
Daping Hospital and the Research Institute of Surgery...

Completed

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Non-small-cell Lung Cancer | Multiple Brain Metastases

China
Hoffmann-La Roche

Completed

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Russian Federation
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hungary, Latvia, Turkey
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Completed

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

Non-Small Cell Lung Cancer

India
GlaxoSmithKline

Withdrawn

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Cancer
European Organisation for Research and Treatment...

Completed

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
Georgetown University

Unknown

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
National Guard Health Affairs

Suspended

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
Qilu Hospital of Shandong University

Not yet recruiting

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Breast Cancer
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
Henan Cancer Hospital

Completed

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Soft Tissue Sarcomas

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

China
Nantes University Hospital

Completed

Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial (DeprescrIPPDAM)

Proton Pump Inhibitors | Deprescription

France
University Hospital, Lille
Ministry of Health, France

Terminated

Advanced Nurses vs. General Practitioners for the Management of Outpatient Alcohol Detox: a Safety and Cost Comparison (SAMBA)

Alcohol Dependence

France
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

Canada
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
University Hospital, Bordeaux

Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Seoul National University Hospital

Completed

Effect of Nilotinib in Cerebellar Ataxia Patients

Ataxia, Cerebellar | Ataxia, Progressive

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway

Search clinical trials for: GP Peramprizumab Anlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations